Abstract:Secondary metabolites have played a key role as starting points for drug development programs due to their often unique features compared with synthetically derived molecules. However, limitations related to the discovery and supply of these molecules by biotechnological means led to the retraction of big pharmaceutical companies from this field. The reasons included problems associated with strain culturing, screening, re-discovery, purification and characterization of novel molecules from natural sources. Nevertheless, recent reports have described technical developments that tackle such issues. While many of these reports focus on the identification and characterization of such molecules to enable subsequent chemical synthesis, a biotechnological supply strategy is rarely reported. This may be because production processes usually fall under proprietary research and/or few processes may meet the requirements of a pharmaceutical development campaign. We aimed to bridge this gap for illudin M—a fungal sesquiterpene used for the development of anticancer agents—with the intention to show that biotechnology can be a vital alternative to synthetic processes dealing with small molecules.

Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 2─Development of a Scalable Nickel-Catalyzed Sulfonylation

Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 3─Development of a Scalable Enzymatic Oxidation Process

Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 1─Process History and Development Strategy

Manufacturing Process Development for Belzutifan, Part 2: A Continuous Flow Visible-Light-Induced Benzylic Bromination

Manufacturing Process Development for Belzutifan, Part 6: Ensuring Scalability for a Deoxyfluorination Reaction

Manufacturing Process Development for Belzutifan, Part 3: Completing a Streamlined Through-Process with a Safe and Scalable Oxidation

Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 5─Chemoenzymatic Diastereoselective Fluorination/DKR

Engineering Hydroxylase Activity, Selectivity, and Stability for a Scalable Concise Synthesis of a Key Intermediate to Belzutifan

Process Development and Scale-Up of a Novel Atypical DAT Inhibitor ( S )-CE-123

Development of a Large-Scale Asymmetric Process for Tert-Butanesulfinamide

Toward the Development of a Manufacturing Process for Milvexian: Scale-Up Synthesis of the Side Chain

Development of a Robust and Scalable Process for the Large-Scale Preparation of Vilazodone

Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks

Metal-Catalyzed C–N Bond Forming Reaction Selection and Process Development for the Manufacture of AZD7594

Scalable Process of Spiro(cyclopropane)oxazepane Pyridine Carboxylic Acid Through Kulinkovich, Mitsunobu, and Pd-Catalyzed Intramolecular C–N Coupling

Optimization of the production process for the anticancer lead compound illudin M: downstream processing

Development of a Scalable Synthesis of Mevidalen (LY3154207), an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor

Scalable electrocatalyzed formation of C–O bonds using flow reactor technology

Process Development and Kinetic Analysis in the Green Synthesis of Lomustine

Process Development of a Novel Azetidinyl Ketolide Antibiotic